RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that the Company’s President and Chief Executive Officer, Tod Woolf, Ph.D., will present a corporate overview at the Rodman & Renshaw Global Investment Conference on Friday, September 11, 2009 at 11:15am ET, at the New York Palace Hotel in New York City.
Dr. Woolf will also be participating in a panel discussion on RNAi Therapeutics, taking place on Thursday, September 10, 2009 at 8:25am ET.
A live webcast of Dr. Woolf’s presentation will be available on the “Investors” section of the Company’s website, www.rxipharma.com. A replay of the presentation will be available for 30 days.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi’s founders include world-leading researchers in the RNAi field, such as Dr. Craig Mello, recipient of the 2006 Nobel Prize for Medicine for his co-discovery of RNAi, and Blais University Chair of Molecular Medicine at the University of Massachusetts Medical School.
Potential advantages for the implementation of RNAi in treating disease include low doses with a high potency; a lower toxicity than some traditional forms of treatment, resulting in the body’s acceptance of the treatment as a natural mechanism; the ability for the treatment to interfere with the expression of any gene; a higher specificity for target genes; and an accelerated lead generation.
RXi has encountered breakthroughs in the area of treatment delivery technologies:
- The Oral Delivery of advanced rxRNA compounds to macrophages can be used to treat inflammations, such as Rheumatoid Arthritis
- Local self delivery of rxRNA compounds can target multiple tissues, such as compromised skin, the mucous membranes of the mouth, the lungs, eyes, or rectum.
- Systemic self-delivery of advanced compounds affect target tissues such as the liver, lung, adipocytes, cardiomyocytes, bone marrow, or inflammation sites, in addition to some of the other major organs.
And, there are multiple, multi-billion dollar markets for the treatment. Established indications in research have shown effectiveness in the treatment of arthritis and inflammatory bowel disease, and psoriasis. Emerging research indicates a possible use in treating atherosclerosis and diabetes.